Spinal cord injury treatments improved
Spinal cord injuries (SCI) are the leading cause of disability in the developed world. Trying to find therapeutic solutions is therefore a primary medical objective. Promising experimental studies have been carried out, and several clinical trials have even been published that use autologous mesenchymal stem cells derived from bone marrow, administered intramedularally.
Scientists have now discovered the possibility of spinal cord injury treatments could be administrated intravenously in humans, which simplifies and avoids risks substantially. The authors conclude that “[their] observations provide evidence supporting the feasibility, safety and functional improvements of infused MSCs into patients with SCI.” (read HERE) As using adult stem cells presents no bioethical difficulties, this experiment can be classified as very positive.